Ablative Solutions wins CE Mark approval in the European Union for its Peregrine infusion ablation catheter for treating uncontrolled hypertension.
Ablative Solutions said it received CE Mark approval for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.
Boston Scientific launches a clinical trial of its Vessix renal denervation device in treating hypertension, aiming to separate its effects from drug therapy for high blood pressure.
ReCor Medical raises a $15 million Series D financing for a planned U.S. study of its ultrasound renal denervation device.
A Japanese healthcare conglomerate is the lead investor ReCor Medical's $15 million Series D round ReCor plans to use to back a U.S. clinical trial of its ultrasound renal denervation device.
Medtronic launches a new clinical trial examining renal denervation as a treatment for hypertension, aiming to settle the 'confounding factors' that led to the failure of its Symplicity-3 trial.
Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
Verve Medical raises just less than $2 million in an equity offering for its renal denervation device.
Stealthy renal denervation startup Verve Medical raised close to $2 million, according to a regulatory filing, with funding likely slated to help support clinical trials.
Rox Medical's stent-like Coupler implant, designed to treat resistant hypertension, fares well in a pivotal trial as the company gears up for a run at an investigational device exemption from the FDA.